Phase Genomics

The company was founded by Ivan Liachko and Shawn Sullivan in 2015. It was originally housed in the CoMotion biotech incubator at University of Washington before relocating to a separate facility. It develops proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes, assemble genomes, understand microbial communities, and identify structural variation in the human genome associated with conditions such as cancer and infertility. The company sells proximity ligation kits, scientific services, and computational analyses.[1]

Phase Genomics developed a line of library preparation kit for the Hi-C sequencing method previously developed by researchers Job Dekker and Eric Lander. The kits are used to study the architecture of genomes in a variety of organisms and sample types.[2] In 2018, Phase Genomics received a $1.5 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to research antimicrobial resistance using Hi-C technology. In January 2020, it was awarded an additional $1.5 million from NIAID for phase 2 SBIR funding.[3] In 2019, Phase Genomics received $200,000 from the Bill & Melinda Gates Foundation to improve computational methods of extracting genomic data in microbiome samples.[3][4] Later in 2019, the company was awarded $325,000 from the U.S. Department of Energy to research algae biofuels using proximity litigation technology for metagenome assembly.[4] In 2020, Phase Genomics received 2 grants totaling $3.9 million from the National Human Genome Research Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The 3-year grants fund research on chromosomal abnormalities causing cancer, infertility, and reproductive issues.[1]

Phase Genomics offers its Proximo™ genome scaffolding & finishing product line for use assembling animal, plant, fungal, and other eukaryote genomes. Its ProxiMeta™ product provides a suite of functionality for culture-free assembly, antimicrobial resistance detection and tracking, plasmid:host and virus:host association, and microbial metabolic analysis. In October 2022, Phase Genomic released a beta version of its CytoTerra™ platform, a product aimed at identifying genomic causes of infertility and the first in a line of cytogenetic products based on proximity ligation.

• Official website